Literature DB >> 9183307

Haemophilia prophylaxis in young patients--a long-term follow-up.

T Löfqvist1, I M Nilsson, E Berntorp, H Pettersson.   

Abstract

OBJECTIVES: To review long-term prophylactic factor treatment in young patients with severe haemophilia A and B, focusing on the orthopaedic and radiological outcome.
DESIGN: We received 34 patients with severe haemophilia A (n = 29) and B (n = 5), aged 7-22 years. Age at start of treatment was 1-4.5 years. Dosages of factor concentrate (F VIII and F IX, respectively) were 25-40 IU/kg body weight, three times a week for haemophilia A and twice a week for haemophilia B. The patients had been checked annually over a 5-year period (1990-95). Orthopaedic and radiological joint scores were evaluated according to recommendations by the World Federation of Haemophilia.
SETTING: All results were obtained at the Department for Coagulation Disorders, University of Lund, Malmö University Hospital, Malmö, Sweden.
RESULTS: Orthopaedic and radiological joint scores were found to have remained unchanged during follow-up in almost all patients and to be still zero (i.e. no unaffected joints) in 79% (n = 27) of the patients.
CONCLUSION: There is a growing international consensus haemophilic arthropathy can be prevented by administering early high-dose prophylaxis. The results of the present investigation strongly support this opinion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9183307     DOI: 10.1046/j.1365-2796.1997.130135000.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  43 in total

Review 1.  Gene therapy for the hemophilias.

Authors:  M A Kay; K High
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.

Authors:  Kathelijn Fischer; Maurice E Pouw; Daniel Lewandowski; Mart P Janssen; H Marijke van den Berg; Ben A van Hout
Journal:  Haematologica       Date:  2011-01-27       Impact factor: 9.941

Review 3.  Adeno-associated virus-mediated gene transfer for hemophilia B.

Authors:  Katherine A High
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 4.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Nat Rev Genet       Date:  2011-05       Impact factor: 53.242

Review 5.  Secondary prophylaxis in adolescent and adult haemophiliacs.

Authors:  Annarita Tagliaferri; Caterina Di Perna; Gianna Franca Rivolta
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

6.  Prophylaxis for adults with haemophilia: one size does not fit all.

Authors:  Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-04       Impact factor: 3.443

7.  Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX.

Authors:  Wei Lu; Qingzhang Zhou; Hao Yang; Hao Wang; Yexing Gu; Qi Shen; Jinglun Xue; Xiaoyan Dong; Jinzhong Chen
Journal:  Front Med       Date:  2016-04-06       Impact factor: 4.592

8.  Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.

Authors:  Alexander H Miners; Caroline A Sabin; Keith H Tolley; Christine A Lee
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

9.  Recombinant factor VIII in the management of hemophilia A: current use and future promise.

Authors:  Jerry S Powell
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

Review 10.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.